Table 1 Epidemiological parameters of preterm neonates and infants with BPD or CHD, and clinical efficacy of palivizumab in preventing RSV-related hospitalizations

Probability of hospitalization in preterm neonates with RSV infection without palivizumab.

34.9%

[8]

Probability of hospitalization in infants with BPD with RSV infection without palivizumab.

25.6%

[3]

Probability of hospitalization in infants with CHD with RSV infection without palivizumab.

19.4%

[5]

Annual frequency of hospitalizations in neonates and infants with RSV infection.

2.52

[10]

Efficacy of palivizumab to prevent RSV-related hospitalizations in preterm neonates ≤ 35 wGA

78.1% (95% CI: 24.0 − 41.3%)

[3]

Efficacy of palivizumab to prevent RSV-related hospitalizations in infants with BPD.

38.5% (95% CI: 4.95 − 60.2%)

[3]

Efficacy of palivizumab to prevent RSV-related hospitalizations in infants with CHD.

45.3% (95% CI: 18.1 − 63.5%)

[5]

Probability of developing wheezing in neonates and infants with RSV infection.

23.9% (95% CI: 15.9 − 35.8%)

[11, 17]

Annual frequency of relapses due to wheezing in neonates and infants with RSV infection.

4.63 (95% CI: 3.70–5.78)

[14]